lactic acid has been researched along with Osteoporosis in 26 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We developed a calcium phosphate cement containing arbekacin sulfate and polylactic acid (CPC95AP) and examined its effects on bone strength by injecting the CPC95AP into the femoral medullary cavity in model rats with osteoporosis." | 7.71 | Mechanical properties of the femur after injection of calcium phosphate cement containing arbekacin sulfate and polylactic acid in a rat model of experimental osteoporosis. ( Ishii, Y; Tanaka, A, 2002) |
| "Twenty-four female Wistar rats (250-300 g, 12 weeks old) were divided into 4 groups: sham group (control), OVX-induced osteoporosis group (OVX), OVX and biodegradable poly(lactic-co-glycolic acid) (PLGA) without tricalcium phosphate (β-TCP) screw insertion group (OVX/BSR), and OVX and biocomposite (PLGA with β-TCP) screw insertion group (OVX/CSR)." | 3.85 | The Effect of Biocomposite Screws on Bone Regeneration in a Rat Osteoporosis Model. ( Choi, KH; Jeon, SR; Jeong, JH; Jin, ES; Kim, JY; Lee, B; Lee, M; Min, J, 2017) |
| " These NPs are expected to enable the transport of drugs, such as simvastatin (SIM), for the treatment of osteoporosis." | 3.81 | Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. ( Chai, G; Hu, FQ; Liu, J; Tao, S; Wang, H; Wang, J; Yuan, H, 2015) |
| "We developed a calcium phosphate cement containing arbekacin sulfate and polylactic acid (CPC95AP) and examined its effects on bone strength by injecting the CPC95AP into the femoral medullary cavity in model rats with osteoporosis." | 3.71 | Mechanical properties of the femur after injection of calcium phosphate cement containing arbekacin sulfate and polylactic acid in a rat model of experimental osteoporosis. ( Ishii, Y; Tanaka, A, 2002) |
| "Here we show that bone resorption of differentiated osteoclasts heavily relies on increased aerobic glycolysis and glycolysis-derived lactate production." | 1.56 | Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis. ( Adam, S; Böhm, C; Böttcher, M; Faas, M; Hofmann, J; Krishnacoumar, B; Krönke, G; Mougiakakos, D; Müller, DIH; Schett, G; Scholtysek, C; Sonnewald, U; Stoll, C; Taubmann, J, 2020) |
| " From these results, it was revealed that E2-loaded PLGA nanoparticles with iontophoresis were useful to recover bone mineral density of cancellous bone, and it was also suggested that they extend the dosing interval of E2." | 1.46 | Estradiol-loaded PLGA nanoparticles for improving low bone mineral density of cancellous bone caused by osteoporosis: Application of enhanced charged nanoparticles with iontophoresis. ( Hida, Y; Kobayashi, S; Makino, K; Takeuchi, I, 2017) |
| " Our aim was to test whether polylactic acid-polyglycolic acid copolymer(PLGA)/collagen type I(CoI) microspheres combined with BMSCs could be used as injectable scaffolds to improve bone quality in osteoporotic female rats." | 1.38 | Improvement of intertrochanteric bone quality in osteoporotic female rats after injection of polylactic acid-polyglycolic acid copolymer/collagen type I microspheres combined with bone mesenchymal stem cells. ( Li, C; Liu, X; Shi, X; Sun, H; Yang, X; Yu, Z; Zhu, T, 2012) |
| "Osteopenia has been associated with antiretroviral therapy, particularly with protease inhibitors." | 1.31 | Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. ( Carr, A; Cooper, DA; Eisman, JA; Miller, J, 2001) |
| " Overall, we believe 1 alpha-hydroxyvitamin D3 with calcium supplement can be considered a safe and effective agent for long-term use in osteoporotic patients." | 1.28 | Long-term treatment with 1 alpha-hydroxyvitamin D3 with calcium supplement in spinal osteoporotic patients. ( Itoi, E; Kasama, F; Sakurai, M; Sato, K; Yamada, Y, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, Z | 1 |
| Lu, Y | 1 |
| Shi, Y | 1 |
| Jiang, M | 2 |
| Shan, X | 1 |
| Li, X | 1 |
| Zhang, J | 1 |
| Qin, B | 1 |
| Liu, X | 2 |
| Guo, X | 1 |
| Huang, J | 1 |
| Liu, Y | 1 |
| Wang, S | 1 |
| Li, Q | 1 |
| Luo, L | 1 |
| You, J | 1 |
| Kaur, M | 1 |
| Nagpal, M | 1 |
| Grewal, AK | 1 |
| Chauhan, S | 1 |
| Dora, CP | 1 |
| Singh, TG | 1 |
| Wu, J | 1 |
| Hu, M | 1 |
| Jiang, H | 1 |
| Ma, J | 1 |
| Xie, C | 1 |
| Zhang, Z | 1 |
| Zhou, X | 2 |
| Zhao, J | 1 |
| Tao, Z | 1 |
| Meng, Y | 1 |
| Cai, Z | 1 |
| Song, T | 1 |
| Zhang, C | 1 |
| Gao, R | 1 |
| Cai, C | 1 |
| Song, H | 1 |
| Gao, Y | 1 |
| Lin, T | 1 |
| Wang, C | 1 |
| Taubmann, J | 1 |
| Krishnacoumar, B | 1 |
| Böhm, C | 1 |
| Faas, M | 1 |
| Müller, DIH | 1 |
| Adam, S | 1 |
| Stoll, C | 1 |
| Böttcher, M | 1 |
| Mougiakakos, D | 1 |
| Sonnewald, U | 1 |
| Hofmann, J | 1 |
| Schett, G | 1 |
| Krönke, G | 1 |
| Scholtysek, C | 1 |
| Takeuchi, I | 2 |
| Kobayashi, S | 2 |
| Hida, Y | 1 |
| Makino, K | 3 |
| Sezlev Bilecen, D | 1 |
| Rodriguez-Cabello, JC | 1 |
| Uludag, H | 1 |
| Hasirci, V | 1 |
| Jeong, JH | 1 |
| Jin, ES | 1 |
| Kim, JY | 1 |
| Lee, B | 1 |
| Min, J | 1 |
| Jeon, SR | 1 |
| Lee, M | 1 |
| Choi, KH | 1 |
| van de Watering, FC | 1 |
| Laverman, P | 1 |
| Cuijpers, VM | 1 |
| Gotthardt, M | 1 |
| Bronkhorst, EM | 1 |
| Boerman, OC | 1 |
| Jansen, JA | 1 |
| van den Beucken, JJ | 1 |
| Bae, J | 1 |
| Park, JW | 1 |
| Fazil, M | 1 |
| Hassan, MQ | 1 |
| Baboota, S | 1 |
| Ali, J | 1 |
| Pei, M | 1 |
| Li, J | 1 |
| McConda, DB | 1 |
| Wen, S | 1 |
| Clovis, NB | 1 |
| Danley, SS | 1 |
| Wang, H | 1 |
| Liu, J | 1 |
| Tao, S | 1 |
| Chai, G | 1 |
| Wang, J | 1 |
| Hu, FQ | 1 |
| Yuan, H | 1 |
| Jia, P | 1 |
| Chen, H | 1 |
| Kang, H | 1 |
| Qi, J | 1 |
| Zhao, P | 1 |
| Guo, L | 1 |
| Zhou, Q | 1 |
| Qian, ND | 1 |
| Zhou, HB | 1 |
| Xu, YJ | 1 |
| Fan, Y | 1 |
| Deng, LF | 1 |
| Fukuda, K | 1 |
| Yu, Z | 1 |
| Zhu, T | 1 |
| Li, C | 1 |
| Shi, X | 1 |
| Yang, X | 1 |
| Sun, H | 1 |
| Thamake, SI | 1 |
| Raut, SL | 1 |
| Gryczynski, Z | 1 |
| Ranjan, AP | 1 |
| Vishwanatha, JK | 1 |
| Otsuka, M | 1 |
| Uenodan, H | 1 |
| Matsuda, Y | 1 |
| Mogi, T | 1 |
| Ohshima, H | 1 |
| Perugini, P | 1 |
| Genta, I | 1 |
| Conti, B | 1 |
| Modena, T | 1 |
| Cocchi, D | 1 |
| Zaffe, D | 1 |
| Pavanetto, F | 1 |
| Ignjatovic, N | 2 |
| Ajdukovic, Z | 2 |
| Uskokovic, D | 2 |
| Zaghloul, AA | 1 |
| Mustafa, F | 1 |
| Siddiqui, A | 1 |
| Khan, M | 1 |
| Zorica, A | 1 |
| Nenad, I | 1 |
| Petrović, D | 1 |
| Dragan, P | 1 |
| Dragan, U | 1 |
| Yang, Q | 1 |
| Owusu-Ababio, G | 1 |
| Carr, A | 1 |
| Miller, J | 1 |
| Eisman, JA | 1 |
| Cooper, DA | 1 |
| Tanaka, A | 1 |
| Ishii, Y | 1 |
| Itoi, E | 1 |
| Yamada, Y | 1 |
| Sakurai, M | 1 |
| Sato, K | 1 |
| Kasama, F | 1 |
| Steidl, L | 1 |
| Ditmar, R | 1 |
1 trial available for lactic acid and Osteoporosis
| Article | Year |
|---|---|
Substitution of osteoporotic alveolar bone by biphasic calcium phosphate/poly-DL-lactide-co-glycolide biomaterials.
Topics: Adult; Biocompatible Materials; Bone Substitutes; Calcium Phosphates; Female; Humans; Lactic Acid; M | 2007 |
25 other studies available for lactic acid and Osteoporosis
| Article | Year |
|---|---|
Neutrophil hitchhiking for drug delivery to the bone marrow.
Topics: Bone Marrow; Humans; Lactic Acid; Nanoparticles; Neutrophils; Osteoporosis; Polyglycolic Acid; Polyl | 2023 |
Molecular Complex of HSIM-loaded Polymeric Nanoparticles: Potential Carriers in Osteoporosis.
Topics: Animals; Delayed-Action Preparations; Drug Carriers; Hydroxyapatites; Hydroxymethylglutaryl-CoA Redu | 2023 |
Endothelial Cell-Derived Lactate Triggers Bone Mesenchymal Stem Cell Histone Lactylation to Attenuate Osteoporosis.
Topics: Animals; Endothelial Cells; Histones; Humans; Lactic Acid; Mesenchymal Stem Cells; Mice; Osteoporosi | 2023 |
Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis.
Topics: Animals; Antimetabolites; Bone Resorption; Cells, Cultured; Deoxyglucose; Female; Glycolysis; Lactic | 2020 |
Estradiol-loaded PLGA nanoparticles for improving low bone mineral density of cancellous bone caused by osteoporosis: Application of enhanced charged nanoparticles with iontophoresis.
Topics: Administration, Cutaneous; Animals; Bone Density; Bone Density Conservation Agents; Cancellous Bone; | 2017 |
Construction of a PLGA based, targeted siRNA delivery system for treatment of osteoporosis.
Topics: Base Sequence; Drug Carriers; Durapatite; Gene Knockdown Techniques; Lactic Acid; Osteoporosis; Part | 2017 |
The Effect of Biocomposite Screws on Bone Regeneration in a Rat Osteoporosis Model.
Topics: Animals; Bone Density; Bone Regeneration; Bone Screws; Calcium Phosphates; Female; Lactic Acid; Oste | 2017 |
The biological performance of injectable calcium phosphate/PLGA cement in osteoporotic rats.
Topics: Animals; Bone Cements; Bone Regeneration; Bone Substitutes; Calcium Phosphates; Disease Models, Anim | 2013 |
Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Del | 2015 |
Biodegradable intranasal nanoparticulate drug delivery system of risedronate sodium for osteoporosis.
Topics: Administration, Intranasal; Drug Carriers; Drug Delivery Systems; Humans; Lactic Acid; Nanoparticles | 2016 |
A comparison of tissue engineering based repair of calvarial defects using adipose stem cells from normal and osteoporotic rats.
Topics: Adipocytes; Animals; Azo Compounds; Bone Regeneration; Cell Proliferation; Female; Lactic Acid; Oste | 2015 |
Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.
Topics: 3T3 Cells; Animals; Bone and Bones; Cell Differentiation; Chromatography, High Pressure Liquid; Drug | 2015 |
Deferoxamine released from poly(lactic-co-glycolic acid) promotes healing of osteoporotic bone defect via enhanced angiogenesis and osteogenesis.
Topics: Animals; Bone Regeneration; Cells, Cultured; Deferoxamine; Female; Femur; Human Umbilical Vein Endot | 2016 |
Transdermal delivery of estradiol-loaded PLGA nanoparticles using iontophoresis for treatment of osteoporosis.
Topics: Administration, Cutaneous; Animals; Bone Density; Drug Delivery Systems; Estradiol; Estrogens; Femal | 2016 |
Improvement of intertrochanteric bone quality in osteoporotic female rats after injection of polylactic acid-polyglycolic acid copolymer/collagen type I microspheres combined with bone mesenchymal stem cells.
Topics: Animals; Bone Density; Bone Marrow Cells; Coated Materials, Biocompatible; Collagen Type I; Disease | 2012 |
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezom | 2012 |
Therapeutic effect of in vivo sustained estradiol release from poly (lactide-co-glycolide) microspheres on bone mineral density of osteoporosis rats.
Topics: Animals; Area Under Curve; Biocompatible Materials; Bone Density; Calcium; Delayed-Action Preparatio | 2002 |
PLGA microspheres for oral osteopenia treatment: preliminary "in vitro"/"in vivo" evaluation.
Topics: Animals; Bone Remodeling; Disease Models, Animal; Drug Carriers; Drug Compounding; Female; Injection | 2003 |
New biocomposite [biphasic calcium phosphate/ poly-DL-lactide-co-glycolide/biostimulative agent] filler for reconstruction of bone tissue changed by osteoporosis.
Topics: Animals; Bone Substitutes; Calcium Phosphates; Female; Fibrin Tissue Adhesive; Lactic Acid; Material | 2005 |
Response surface methodology to obtain beta-estradiol biodegradable microspheres for long-term therapy of osteoporosis.
Topics: Biodegradation, Environmental; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Emulsions | 2006 |
Biodegradable progesterone microsphere delivery system for osteoporosis therapy.
Topics: Antimicrobial Cationic Peptides; Biodegradation, Environmental; Drug Compounding; Drug Delivery Syst | 2000 |
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
Topics: Absorptiometry, Photon; Acidosis, Lactic; Adult; Anti-HIV Agents; Body Composition; Body Weight; Bon | 2001 |
Mechanical properties of the femur after injection of calcium phosphate cement containing arbekacin sulfate and polylactic acid in a rat model of experimental osteoporosis.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Biocompatible Materials; Bone Cements; Calcium Phos | 2002 |
Long-term treatment with 1 alpha-hydroxyvitamin D3 with calcium supplement in spinal osteoporotic patients.
Topics: Aged; Aged, 80 and over; Bone Density; Cholestanetriol 26-Monooxygenase; Female; Humans; Lactates; L | 1992 |
Osteoporosis treated with magnesium lactate.
Topics: Aged; Aged, 80 and over; Female; Humans; Lactates; Lactic Acid; Male; Middle Aged; Osteoporosis | 1991 |